Gilead Sciences Total Assets 2006-2021 | GILD

Gilead Sciences total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Gilead Sciences total assets for the quarter ending September 30, 2021 were $67.098B, a 10.22% increase year-over-year.
  • Gilead Sciences total assets for 2020 were $68.407B, a 11% increase from 2019.
  • Gilead Sciences total assets for 2019 were $61.627B, a 3.22% decline from 2018.
  • Gilead Sciences total assets for 2018 were $63.675B, a 9.4% decline from 2017.
Gilead Sciences Annual Total Assets
(Millions of US $)
2020 $68,407
2019 $61,627
2018 $63,675
2017 $70,283
2016 $56,977
2015 $51,716
2014 $34,664
2013 $22,579
2012 $21,240
2011 $17,303
2010 $11,593
2009 $9,699
2008 $6,937
2007 $5,835
2006 $4,086
2005 $3,766
Gilead Sciences Quarterly Total Assets
(Millions of US $)
2021-09-30 $67,098
2021-06-30 $67,984
2021-03-31 $67,492
2020-12-31 $68,407
2020-09-30 $60,878
2020-06-30 $55,934
2020-03-31 $59,741
2019-12-31 $61,627
2019-09-30 $59,146
2019-06-30 $63,210
2019-03-31 $62,837
2018-12-31 $63,675
2018-09-30 $64,305
2018-06-30 $65,355
2018-03-31 $65,381
2017-12-31 $70,283
2017-09-30 $64,662
2017-06-30 $60,263
2017-03-31 $57,701
2016-12-31 $56,977
2016-09-30 $56,609
2016-06-30 $49,980
2016-03-31 $47,765
2015-12-31 $51,716
2015-09-30 $50,637
2015-06-30 $39,167
2015-03-31 $38,321
2014-12-31 $34,664
2014-09-30 $28,844
2014-06-30 $31,206
2014-03-31 $28,078
2013-12-31 $22,579
2013-09-30 $22,468
2013-06-30 $22,624
2013-03-31 $22,212
2012-12-31 $21,240
2012-09-30 $20,964
2012-06-30 $20,502
2012-03-31 $19,950
2011-12-31 $17,303
2011-09-30 $12,640
2011-06-30 $12,694
2011-03-31 $12,987
2010-12-31 $11,593
2010-09-30 $11,456
2010-06-30 $10,497
2010-03-31 $10,696
2009-12-31 $9,699
2009-09-30 $8,937
2009-06-30 $8,387
2009-03-31 $7,520
2008-12-31 $6,937
2008-09-30 $6,974
2008-06-30 $6,517
2008-03-31 $5,879
2007-12-31 $5,835
2007-09-30 $5,318
2007-06-30 $4,826
2007-03-31 $4,615
2006-12-31 $4,086
2006-09-30 $5,299
2006-06-30 $5,180
2006-03-31 $4,037
2005-12-31 $3,766
2005-09-30 $2,919
2005-06-30 $2,688
2005-03-31 $2,369
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $86.352B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.639B 8.76
Bio-Rad Laboratories (BIO.B) United States $16.992B 34.48
QIAGEN (QGEN) Netherlands $10.895B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $7.620B 0.00
Emergent Biosolutions (EBS) United States $2.497B 8.98
Arcus Biosciences (RCUS) United States $2.167B 0.00
Myovant Sciences (MYOV) United Kingdom $1.222B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.110B 0.00
Zymeworks (ZYME) Canada $0.466B 0.00
SQZ Biotechnologies (SQZ) United States $0.206B 0.00
Ambrx Biopharma (AMAM) United States $0.195B 0.00
Enzo Biochem (ENZ) United States $0.157B 20.19